Current Cardiology Reports

, Volume 1, Issue 2, pp 88–90 | Cite as

Duration and intensity of anticoagulation among patients with genetic predispositions to venous thrombosis

  • Paul M. Ridker
Clinical Trials Review

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Price DT, Ridker PM: Factor V Leiden mutation and the risks of thromboembolic disease: A clinical perspective. Ann Intern Med 1997, 127:895–903.PubMedGoogle Scholar
  2. 2.
    Koster T, Rosendaal FR, de Ronde H, et al.: Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993, 342:1503–1506.PubMedCrossRefGoogle Scholar
  3. 3.
    Ridker PM, Hennekens CH, Lindpaintner K, et al.: Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995, 332:912–917.PubMedCrossRefGoogle Scholar
  4. 4.
    Poort SR, Rosendaal FR, Reitsma PH, Bertina RM: A common genetic variation in the 3'-untraslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996, 88:3698–3703.PubMedGoogle Scholar
  5. 5.
    Ridker PM, Hennekens CH, Miletich JP: G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men. Circulation 1999, 99:999–1004.PubMedGoogle Scholar
  6. 6.
    Ridker PM, Miletich JP, Stampfer MJ, et al.: Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation 1995, 92:2800–2802.PubMedGoogle Scholar
  7. 7.
    Simioni P, Prandoni P, Lensing AW, et al.: The risk of recurrent venous thromboembolism in patients with an Arg506-Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med 1997, 336:399–403.PubMedCrossRefGoogle Scholar
  8. 8.
    The Research Committee of the British Thoracic Society: Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Lancet 1992, 340:873–876.Google Scholar
  9. 9.
    Schulman S, Rhedin AS, LIndmaker P, et al.: A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995, 332:1661–1665.PubMedCrossRefGoogle Scholar
  10. 10.
    Schulman S, Granqvist S, Holmstrom M, et al.: The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 1997, 336:393–398.PubMedCrossRefGoogle Scholar
  11. 11.
    Kearon C, Gent M, Hirsh J, et al.: A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999, 340:901–907.PubMedCrossRefGoogle Scholar
  12. 12.
    Ridker PM, Hennekens CH, Selhub J, et al.: Interrelation of hyperhomocystinemia, factor V Leiden, and risks of future venous thromboembolism. Circulation 1997, 95:1777–1782.PubMedGoogle Scholar
  13. 13.
    Ridker PM for the PREVENT Investigators: Long-term, lowdose warfarin among venous thrombosis patients with and without factor V Leiden mutation: rationale and design for the Prevention of Recurrent Venous Thromboembolism (PREVENT) trial. Vascular Medicine 1998, 3:67–73.PubMedGoogle Scholar

Copyright information

© Current Science Inc 1999

Authors and Affiliations

  • Paul M. Ridker
    • 1
  1. 1.Divisions of Cardiovascular Diseases and Preventive MedicineBrigham and Women's Hospital, Harvard Medical SchoolBostonUSA

Personalised recommendations